Viral Hepatitis Market to Hit $19.01B by 2028 Growing at 4.7% CAGR, Fueled by Health Initiatives and Combination Therapies

The viral hepatitis market size has grown steadily in recent years. It will grow from $15.48 billion in 2023 to $16.21 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.01 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.

Market Overview -
Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Elevated Prevalence Of Hepatitis Driving Growth In The Viral Hepatitis Market
The rising prevalence of hepatitis is expected to propel the growth of the viral hepatitis market going forward. Hepatitis is an infection of the liver caused by several infectious viruses and non-infectious substances, which can result in several medical issues. Hepatitis A, B, C, D and E are among the viruses that can cause viral hepatitis, which results in liver inflammation and damage. For instance, in August 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, there were about 9,952 hepatitis A cases reported by 49 states and the District of Columbia in 2020 and 4,798 acute hepatitis C cases were reported to CDC from 44 states in 2020. Further, in 2020, 41 states reported a total of 107,300 newly discovered cases of chronic hepatitis C to the CDC. Therefore, the rising prevalence of hepatitis will drive the viral hepatitis market.

Competitive Landscape -
Major players in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd. .

Leading Companies In The Viral Hepatitis Market Drive Innovation And Drug Development
Companies operating in the viral hepatitis market are working on advancing new drugs and development to sustain their position in the market. Drug development and innovation boost scientific understanding by giving insights into disease mechanisms and accelerating the development of new treatments. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) had granted the supplemental new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily medication to treat chronic hepatitis B virus (HBV) infection in children 12 years of age and older with compensated liver disease. The 24-week Phase 2 clinical trial results supported Vemlidy's approval in this group of pediatric patients.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Key Segments -
The viral hepatitis market covered in this report is segmented -
1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.